Skip to main content


Log in

Developmental strategy for swellable/erodible matrix tablet of mirabegron: quality by design approach with various geometric properties and pharmacokinetic evaluation

  • Original Article
  • Published:
Journal of Pharmaceutical Investigation Aims and scope Submit manuscript



This study aimed to establish a developmental strategy for swellable and erodible matrix tablets containing mirabegron using a quality by design approach with geometric properties such as gel strength, erosion rate, and swelling rate.


The design of the experiment (DoE) was used to investigate the effects of critical material attributes (CMAs) on critical quality attributes (CQAs) and geometric properties. Pearson correlation coefficients were used to determine the relationship between geometric properties and CQAs. To evaluate the pharmacokinetics of mirabegron following oral administrations of the test and reference formulations, in vivo pharmacokinetic study was carried out using Beagle dogs.


As a result of DoE, (%) dissolved drug amount and geometric properties were significantly related to CMAs. A robust design space was established with low absolute and relative biases between prediction and experimental results. Pearson correlation coefficients showed significant correlations between (%) dissolved drug amount and geometric properties. The geometric mean ratios of the maximum plasma concentration and area under the concentration–time curve between test and reference formulations were 0.954 and 1.050, respectively. No significant differences in all pharmacokinetic parameters were observed between reference and test drug-treated groups (p < 0.05, t-test).


These results show the usefulness of the developmental strategies using various geometric properties while developing a swellable/erodible matrix tablet.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others


Download references

Author information

Authors and Affiliations


Corresponding author

Correspondence to Du Hyung Choi.

Ethics declarations

Conflict of interest

All authors (J.Y. Kim, T.H. Kim, E Kim, and D.H. Choi) declare no conflicts of interest.

Human and Animal Rights

The animal experimental protocols were approved, and all animals received care in compliance with the guidelines of the Animal Care Committee of HLB BioStep Co., Ltd. (BIOSTEP IACUC 23-KE-0155).

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (DOCX 1253 kb)

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kim, J.Y., Kim, T.H., Kim, E. et al. Developmental strategy for swellable/erodible matrix tablet of mirabegron: quality by design approach with various geometric properties and pharmacokinetic evaluation. J. Pharm. Investig. 53, 881–894 (2023).

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: